Meirluc,
I certainly don't know, but I don't believe the loading, unloading, and operation of the EDEN Unit is rocket science to the people who're already working in cleanrooms and routinely making other things in this environment. I can't say how NWBO would handle qualifying people to operate the EDEN Units, but I suspect they'd either have FlaskWorks operate a training and certifying facility, and personnel who'll be responsible for their operation at other sites would attend classes, or FlaskWorks would transport a number of EDEN Units to the site that's being licensed to utilize the EDEN's to make DCVax-L and FlaskWorks personnel would train and certify the personnel at that site.
I suspect that FlaskWorks would go to and certify each site bringing sufficient EDEN Units to get them started. Post training additional new EDEN Units could be shipped to site and personnel there would already be trained on how to properly unpack and install the new units.
I certainly don't know how many units a month the contractors working for the company can deliver, I hope it's at least in the hundreds, if not the thousands a month.
With sufficient delivery of EDEN Units, I believe the company will be able to identify existing facilities willing to contract with NWBO for the commercial production of DCVax-L in substantial quantities.
In short, I believe that if the demand is there, NWBO can identify sufficient places to meet the demand provided their contractors can manufacture sufficient quantities of the EDEN Units.
If I'm right about this, while it may take a few months, NWBO could deal with a tumor agnostic finding first for the UK, but ultimately for the remainder of the planet.
Gary
Bullish
Market Data 
Markets 
AI
